ليتروزول تيڤع

País: Israel

Idioma: àrab

Font: Ministry of Health

ingredients actius:

LETROZOLE 2.5 MG

Disponible des:

TEVA PHARMACEUTICAL INDUST.LTD

Codi ATC:

L02BG04

formulario farmacéutico:

TABLETS

Vía de administración:

PER OS

Fabricat per:

TEVA PHARMACEUTICAL INDUSTRIES LTD

Grupo terapéutico:

LETROZOLE

indicaciones terapéuticas:

Letrozole teva tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined, locally advanced or metastatic breast cancer: Letrozole teva is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Data d'autorització:

2010-01-01